Achillion Pharmaceuticals News

Achieves Up to 3.73 log10 Reduction in Genotype 1 HCV RNA After Three Days of Treatment With Once-Daily 400 mg ACH-2684 in Phase 1b Study NEW HAVEN, Conn., May 21, 2012 -- Achillion Pharmaceuticals, Inc.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia NEW HAVEN, Conn., May 18, 2012 -- Achillion Pharmaceuticals, Inc.

May 17, 2012 -- Achillion Pharmaceuticals, Inc., a biopharmaceutical company, has received fast track designation from the FDA for ACH-3102 as part of an interferon-free regimen for the treatment of chronic hepatitis C virus, or HCV.

NEW HAVEN, Conn., May 15, 2012 -- Achillion Pharmaceuticals, Inc. /quotes/zigman/100395/quotes/nls/achn ACHN +2.32% announced today the receipt of a Fast Track designation from the U.S. Food and Drug Administration for ACH-3102 as part of an interferon-free regimen for the treatment of chronic hepatitis C . ACH-3102 is a pan-genotypic ... (more)

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia NEW HAVEN, Conn., May 9, 2012 -- Achillion Pharmaceuticals, Inc.

Shares of Achillion Pharmaceuticals opened at 5.99 on Monday. Achillion Pharmaceuticals has a one year low of $3.81 and a one year high of $12.95. The company's market cap is $422.7 million.